These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32229803)

  • 21. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.
    Wang S; Zhao X; Wu S; Cui D; Xu Z
    Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
    Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
    Law AMK; Valdes-Mora F; Gallego-Ortega D
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
    Lu LC; Chang CJ; Hsu CH
    J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
    Wang L; Hu D; Xie B; Xie L
    Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
    Darragh LB; Oweida AJ; Karam SD
    Front Immunol; 2018; 9():3154. PubMed ID: 30766539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.
    Li Q; Xiang M
    Acta Pharmacol Sin; 2022 Jun; 43(6):1337-1348. PubMed ID: 34561553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
    Zhao Y; Du J; Shen X
    Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
    Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.
    Lim J; Lee A; Lee HG; Lim JS
    Biomol Ther (Seoul); 2020 Jan; 28(1):1-17. PubMed ID: 31431006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.